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Summary The frequency of sister chromatid exchange (SCE) was measured in peripheral blood lymphocytes
from control, healthy subjects and immunosuppressed recipients of cadaveric donor kidneys with and without
skin cancer. The mean SCE frequency in 43 control subjects was 9.2 per cell (range 5.4-12.3). In 30 transplant
recipients with no history or evidence of cancer the mean SCE rate was 10.3 per cell (range 5.8-24.5); four
(13%) of these patients had a mean SCE frequency outside the control range. In 7 transplant recipients with
skin cancer, the mean SCE frequency was 14.3 per cell (range 9.1-19.9). This was significantly (P<0.01)
higher than the mean value of control subjects. The mean SCE frequencies in 3 of these 7 patients fell within
the control range and in 4 of these patients was above the control range. These results suggest that some
immunosuppressed kidney transplant recipients are liable to chromosomal damage.
An increased incidence of cancer is well recognized
in renal transplant recipients (Penn, 1979; Sheil et
al., 1981). In these patients, tumours arise
predominantly in the skin, uterine cervix and
lymphoid tissue although primary tumours in a
wide variety of other sites also occur at a higher
incidence than in an age-matched group in the
general community. A number of hypotheses have
been proposed to explain this phenomenon,
generally relating either to immune dysfunction
associated with immunosuppressive therapy, or to
the antigenic stimulation of the graft (Sheil, 1982).
Another factor which may be involved is chemical
carcinogenicity of immunosuppressive agents. It is
to this last possibility that this study is addressed.
A wide variety of drugs and agents are used in
transplantation to achieve immunosuppression,
including azathioprine, corticosteroids, anti-
lymphocyte globulin, actinomycin C, cyclosporin A
and cyclophosphamide. Of these, a combination of
azathioprine (Imuran: Burroughs Wellcome) and
corticosteroids is the usual immunosuppressive
regimen. Of these, azathioprine has been reported
to be mutagenic in the Ames test (Speck &
Rosenberg, 1976) and in a variety of in vivo and in
vitro cellular assays (Pederson, 1964; Nasjleti &
Spencer, 1966; Ripps et al., 1971; Clark, 1975;
Wyrobek & Bruce, 1975; Krogh-Jensen & Hiittle,
1976; Van Went, 1979) as well as being teratogenic
(Thiersch, 1962; Githers et al., 1965).
The results of chromosome studies of humans
receiving azathioprine treatment are inconclusive.
There have been a number of studies carried out in
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non-transplant patients receiving azathioprine
therapy for a variety of disorders. An increased
incidence of chromosomal abnormalities (including
chromatid or chromosomal breaks, fragments and
rearrangements) has been reported in some patients
(Krogh-Jensen, 1967, 1970; Krogh-Jensen &
Soborg, 1966; Eberle et al., 1968) but the increased
incidence was not uniform and it is difficult to
separate the chromosomal damage in those patients
due to azathioprine and that due to the primary
disease process. There are few reports of similar
studies in transplant recipients. In one study of
renal transplant recipients receiving
azathioprine/prednisone therapy (Kingston et al.,
1971), an increased incidence of chromosomal
damage was reported in peripheral blood
lymphocytes (PBL) in some recipients, but this was
attributed to the adjunct radiotherapy that these
patients received rather than to the chemotherapy.
In one other report, an increased incidence of
chromosomal abnormalities was observed in PBL
from both a renal transplant recipient and the new
born child ofthat recipient (Leb et al., 1971).
In this study, chromosome studies were
performed on PBL from renal transplant recipients
who were on maintenance doses of azathioprine
and prednisone and were from 6 months to 9 years
post-transplantation; some of these patients
developed skin cancer (squamous cell carcinoma
and basal cell carcinoma) following transplantation.
The purpose of the study was to see if there was
any evidence of chromosomal damage in kidney
transplant recipients and to relate this to the
development of skin cancer.
Chromosomal damage can be investigated using
the technique of sister chromatid exchange (SCE).
SCE involves the breaking and crossing of a
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segment of deoxyribonucleic acid (DNA) between 2
sister chromatids. While the precise molecular basis
of SCE and its relationship to mutagenesis remain
unclear, there is mounting evidence that the SCE
assay is a reliable indicator of whole body exposure
to mutagenic and carcinogenic chemicals (Perry &
Evans, 1975; Nevstad, 1978; Raposa, 1978)
although not of radiation (Perry & Evans, 1975).
While the relationship between SCE induction and
chromosomal aberration induction is complex, SCE
frequency appears to be a more sensitive assay of
chromosome-damaging agents than other
commonly used assays such as morphological
chromosome studies and presence of micro-nuclei;
moreover the in vivo effects of mutagenic chemicals
are more readily detected by SCE frequency at drug
doses which cause almost no morphological
chromosome damage (Latt, 1974; Perry & Evans,
1975; Abe & Sasaki, 1977).
Materials and methods
Subjects
Blood was collected on single occasions from 45
normal, healthy individuals (controls) presenting as
volunteers to a Blood Transfusion Service. In
addition, 3 individuals from the laboratory staff
were tested for SCE on 4 separate occasions at
approximately monthly intervals.
Fifty-six kidney transplant recipients were tested.
The selection and management of these patients has
been described elsewhere (Sheil et al., 1972). Each
patient had stable graft function and was receiving
maintenance azathioprine (1-2mgkg-1) and
prednisone (0.2-0.5mgkg-1) therapy; most patients
had received a short course of goat anti-human
lymphocyte globulin immediately following
transplantation. Patients with a blood lymphocyte
count <500 cells mm 3 were excluded from the
study; otherwise the 56 patients were randomly
selected from a large pool of transplant recipients.
The group of 56 transplant recipients comprised:
(a) Forty-eight patients with no history or evidence
of cancer. These patients were from 6 months
to 9 years post-transplantation. Each patient
was tested on 2-4 occasions over a 15 month
period;
(b) Eight patients with skin cancer. These patients
were from 44-8 years post-transplantation. In 6
cases the SCE assay was done at the time of
tumour removal and then at least once again
within 3 months; the remaining 2 cases had
multiple, recurring tumours and were assayed
on 4 occasions over a 16-month period at the
times of tumour removals. In each case the
tumour was excised under local anaesthesia; no
radiotherapy or chemotherapy was used.
SCE Assay
PBL were separated from blood by density gradient
centrifugation and 3 x 106 cells cultured in the dark
at 37°C in 4ml RPMI 1640 medium (Flow)
supplemented with 10% human A serum,
glutamine, HEPES buffer, gentamycin and
25 4ugmlF' Phytohaemagglutinin P (PHA; Sigma).
For each control subject, one aliquot of PBL was
cultured for 72h and another aliquot for 96h.
Bromodeoxyuridine (Sigma) was added to a final
concentration of 10 ugml- ' of culture medium 24h
after the start of each culture. Colcemid
(Calbiochem) was added to a concentration of
0.1 Mgml'- medium for the last 2h of culture. The
cells were then treated with 0.075MKCI, fixed in
cold methanol: acetic acid and this suspension
dropped onto glass slides and air dried.
Slides were aged in the dark for 3-6 days and
differential staining of chromatids then done using
an adaption (Goto et al., 1975) of a technique
described by Perry & Wolff (1974). Briefly, the
slides were treated with a 10-4M solution of the
fluorochrome 33258 Hoechst in distilled water for
15min, rinsed, just covered with 0.06MNa2HPO4
solution and exposed to direct sunlight for 2-3h.
Slides were then left in Sorenson's buffer overnight
and subsequently stained with 4% Giemsa. For
each individual, %20 metaphases that showed clear
differential staining were scored.
Results
The reproducibility of the SCE assay is high. Three
control subjects tested on 3-4 occasions at monthly
intervals each displayed little variation in mean
SCE frequency (Table I). A one-way analysis of
variance on these data indicated no significant
difference (P>0.05) between tests. However, not all
PBL samples from the study group responded
adequately to PHA; PBL from 2 control patients,
Table I Results of repeat SCE assays on 3 control
subjects
Mean SCEper cell
Subject Test I Test 2 Test 3 Test 4
1 9.8 7.9 10.4 10.8
2 8.4 9.9 11.3 ND
3 7.7 10.3 8.8 11.1
ND =not determined.SCE IN TRANSPLANT RECIPIENTS 799
18 transplant recipients without cancer and 1
transplant recipient with cancer consistently yielded
low numbers of secondary metaphases on repeated
occasions and were excluded fron the study. The
results of the SCE assays in the remaining 43
control subjects and 37 transplant recipients (30
without cancer, 7 with cancer) are presented in
Table II.
Table II Mean SCE rates in controls and renal
transplant (Tx) patients.
Range of
No. Range of mean SCE/cell
Subjects subjects SCE/cell SCE/cell +s.d.
Controls 43 2-18 5.4-12.3 9.2+2.1
Tx-no cancer 30 4-32 5.8-24.5 10.3+4.0
Tx-cancer 7 4-25 9.1-19.9 14.3+3.9
Of the 37 transplant recipients, in 29 cases the
PBL aliquots cultured for 72h consistently yielded
on repeat assays an adequate percentage of
secondary metaphase spreads with satisfactory
differential chromatid staining and were scored in
preference to the duplicate aliquots cultured for
96h. For the other 8 recipients, (7 without cancer, 1
with cancer) the 96h cultures were found to be
superior on each testing occasion and were thus
preferentially scored.
The mean rate of SCE in the 43 control subjects
in this study was 9.2 per cell (Table II). Here it can
be seen that there are substantial variations between
individuals and between cells of the one individual.
The range of mean SCE frequencies in the control
group was 5.4-12.3, although the 95% confidence
interval for mean SCE frequencies in this group is
5.0-13.4 and all control individuals fell within this
range. Within patients, there was also a substantial
spread of SCE frequencies between metaphases;
within control patients, SCE frequencies ranged
between 2 and 18 per cell.
The mean SCE frequencies of 30 renal transplant
recipients with no history or evidence of cancer was
10.3 (Table II). With a one-way analysis of
variance, this result was not statistically different
(P>0.05) from the mean frequency observed in
control subjects. In 26 of these patients, the mean
frequency fell within the range 5.4-12.3 observed in
the control subjects; further tests on these patients
on 2-3 different occasions showed little variation
and all individual mean test results fell within the
normal range. In the remaining 4 patients, however,
mean SCE frequencies fell outside the normal
range, being 13.9, 14.3, 14.5 and 24.5; each of these
4 patients was tested on 2 separate occasions with
consistent results in each case.
The mean SCE frequency of the 7 recipients with
skin cancer from 2-4 different assays was 14.3 per
cell which is significantly different (P<0.01) by the
analysis of variance test from the mean result in
control subjects.
The individual results of SCE assays in the 7
recipients with cancer are presented in Table III.
Three patients had basal cell carcinoma (BCC); in 2
cases a single tumour and in 1 case, multiple
tumours. Four patients had squamous cell
carcinoma (SCC); in 1 case a single tumour, in
another case multiple tumours, and in 2 cases,
multiple recurring tumours. In 3 cases the mean
SCE frequency (9.1-11.5) was within the range
observed in control subjects, and in 4 cases (15.9-
19.9) it was outside this control range. The degree
of variability between repeated assays of the same
individuals was within the limits of that seen for
control subjects.
Table III SCE frequencies in transplant recipients with
skin cancer (Mean values for 2-4 separate assays)
Patient Cancer type Mean SCE Range'
1 BCC 10.5 (6-14)
2 BCC 15.9 (9-20)
3 BCC2 15.9 (7-25)
4 SCC 9.1 (5-15)
5 SCC2 19.9 (10-23)
6 SCC3 11.5 (4-17)
7 SCC3 17.4 (9-23)
'Values for -80 metaphases accrued from 2-4 separate
assays.
2These patients had multiple tumours at the time of
assay.
3These patients had frequently recurring multiple
tumours.
In 8/37 transplant recipients, SCE rates were
determined from PBL samples cultured for 96h.
Although SCE rates in PBL may increase with time
in culture (Ockey, 1980), in each of these 8 patients,
the mean SCE frequency fell within the control
range (5.4-12.3).
The possibility that environmental factors outside
those associated with transplantation and immuno-
suppressive therapy might influence SCE frequency
was considered. Of the 8 patients whose mean SCE
frequency exceeded the normal range, none had
occupations considered "high-risk" for mutagenesis
and only 1 was a cigarette smoker. There was also
nothing to suggest that these 8 patients had greater
than normal exposure to sunlight.800 G.E. KELLY & A.G.R. SHEIL
Discussion
In this study, PBL were selected because there are
at present no appropriate measures for assaying
chromosomal damage in human germ cells and
therefore an extrapolation from a somatic cell must
be used. Also studies on cultured mammalian cells
and animals or humans exposed to mutagenic
agents have shown that PBL provide reliable and
sensitive indicators of both in vivo and in vitro
induced chromosomal damage (Perry & Evans,
1975; Stetka et al., 1978).
The mean rate of SCE in cultured lymphocytes
from the general population as reported by other
groups varies widely, between 5 and 14 per cell
(Galloway & Evans, 1975; Dauod et al., 1976;
Crossen et al., 1977; Raposa, 1978). It is not clear
how much of this variation is due to real
differences in the various populations studied, but it
is likely that much of it is artefactual, reflecting
relatively small sample numbers and differences in
culture and staining techniques. Similarly, values
reported in those human conditions characterised
by an elevated SCE frequency are variable but are
generally in the order of a 2-3 fold increase
following in vivo exposure to mutagenic agents
(Nevstad, 1978; Raposa, 1978).
The range and mean SCE frequency observed in
control patients in this study is in general
agreement with that reported by others. Moreover,
the assay was reproducible, showing little variation
with time in individuals. However, the intra-subject
variation on a particular test occasion was high and
is difficult to interpret although it has been
observed before (Morgan & Crossen, 1977; Crossen
et al., 1977).
In this study we have investigated the potential
genetic hazard to transplant recipients receiving
immunosuppressive therapy. This may be of
importance because of the increasing number of
transplant recipients having children and the high
incidence of cancer in transplant recipients. Eight of
a total of 37 (22%) of renal transplant recipients
showed elevated SCE rates suggesting in these
patients exposure to mutagenic agents with
consequent chromosomal damage. Whether these
patients will be at increased risk of cancer
development remains to be seen, but the finding
that 4/7 patients with skin cancer had an increased
frequency is suggestive that they might be. While
the increase in SCE frequency in these patients is
not dramatic, any chromosomal damage may add
to other factors which predispose to malignancy
such as exposure to sunlight or oncogenic viruses.
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